Brazil, the largest pharmaceutical market in Latin America, has just removed one of the biggest barriers to entry. Since June 29, 2026, pharmaceutical companies no longer need to have their products registered in another country before applying for registration with ANVISA, the Brazilian health regulatory agency. Combined with a strengthened regulatory reliance framework, this unprecedented reform makes Brazil a market that global companies can now prioritize from day one.
With access to more than 210 million people, a sophisticated healthcare ecosystem, and growing demand for innovative therapies, Brazil has always offered enormous commercial potential. Yet many global companies historically treated it as a secondary launch market due to regulatory complexity and sequential approval requirements.
That landscape has changed.
Two recent regulatory developments, Law No. 15,440/2026, in force since June 29, 2026, and ANVISA’s Normative Instruction No. 451/2026, in force since June 1, 2026, mark a new phase in Brazil’s regulatory evolution. Together, they create a significantly more attractive environment for pharmaceutical, biotechnology, and healthcare companies looking to expand into one of the world’s most important emerging markets.
A Major Shift: Brazil No Longer Needs to Wait
The most significant change introduced by Law No. 15,440/2026 is the removal of the requirement that imported medicines be registered in their country of origin before submission to ANVISA. In practical terms, companies can now consider Brazil much earlier in their global regulatory and commercialization plans.
For innovative medicines (both synthetic and biologic), generics, and biosimilars, this change allows manufacturers to integrate the Brazilian market into initial launch strategies rather than waiting for approvals elsewhere. For organizations managing global development programs, where sequencing decisions directly impact time-to-market and long-term commercial success, the implications are substantial.
The message is clear: Brazil is becoming a market that companies can prioritize, not simply one they address later.
Faster Access Without Lowering Standards
Importantly, the new legislation does not reduce ANVISA’s scientific rigor or quality expectations.
While prior registration in the country of origin is no longer required, the law reinforces the importance of demonstrating compliance with Good Manufacturing Practices (GMP) as part of the registration process. Manufacturers must continue to prove that their products are produced under robust quality systems and internationally accepted standards of safety, quality, and control.
The Growing Impact of Regulatory Reliance
At the same time, ANVISA continues to advance its modernization agenda through the expanded use of regulatory reliance: the ability to leverage inspections, assessments, and certifications conducted by trusted foreign regulatory authorities.
With the publication of IN 451/2026, Brazil strengthened this framework, expanding the use of optimized review procedures and introducing a more targeted approach to regulatory assessment. Most importantly, ANVISA can now focus its review on identified divergences or specific risk areas rather than repeating a full assessment already performed by a recognized foreign authority.
For global companies, this means greater efficiency, reduced regulatory burden, and increased predictability throughout the approval process. It also aligns Brazil more closely with international best practices promoted by leading regulatory agencies and global health organizations.
A More Efficient Path to GMP Certification
The updated reliance framework also enhances the pathway for obtaining the Brazilian Good Manufacturing Practice Certificate (CBPF).
By making greater use of inspections and assessments conducted by recognized foreign regulatory authorities, ANVISA can optimize its certification review process and avoid unnecessary duplication of regulatory efforts. Under the revised framework, assessments may focus on identified gaps or divergences rather than repeating a full evaluation already performed by a trusted authority, promoting a more efficient and risk-based approach.
This is particularly valuable for multinational manufacturers that already operate under the oversight of mature regulatory agencies and maintain internationally recognized compliance programs.
Combined with the changes introduced by Law No. 15,440/2026, the updated framework is expected to bring greater efficiency to GMP certificate assessments, with the potential to streamline regulatory workflows and contribute to shorter review timelines, all while maintaining ANVISA’s high standards for quality, safety, and compliance.
Why This Matters for Global Investors
From an investment perspective, these developments go beyond regulatory reform. They demonstrate Brazil’s commitment to becoming a more integrated participant in the global life sciences ecosystem. Key benefits include:
- Earlier inclusion of Brazil in global launch strategies
- Greater regulatory predictability
- Reduced duplication of regulatory activities
- More efficient GMP certification pathways
- Improved alignment with international regulatory practices
- Increased opportunities for innovative therapies to reach the market
The regulatory reliance framework has also been expanded to additional product categories, including medical cannabis products, further illustrating ANVISA’s commitment to using internationally trusted regulatory decisions where appropriate. This broader scope may create additional opportunities for companies operating in emerging therapeutic segments.
Brazil’s Moment Is Now
The combination of Law No. 15,440/2026 and ANVISA IN 451/2026 marks a milestone in the country’s regulatory journey. By eliminating the prior registration requirement and strengthening reliance-based pathways, Brazil is removing barriers that historically shaped global launch sequencing, while preserving the rigorous quality and safety standards expected from a mature regulatory authority.
For pharmaceutical, biotechnology, and healthcare companies looking to expand internationally, the message is compelling: Brazil is no longer just a large market. It is becoming a strategically accessible one. Organizations that incorporate Brazil into their regulatory and commercial planning early will be best positioned to capitalize on the opportunity.
Turning Opportunity into Market Success with ClarkeModet
A more efficient and investment-friendly regulatory environment still requires deep expertise and local knowledge to navigate. This is where ClarkeModet makes the difference.
With extensive experience in Regulatory Affairs, Intellectual Property, and Innovation Services, ClarkeModet supports international companies throughout the entire process of establishing and expanding their presence in Brazil: from regulatory strategy and product registration to GMP certification support, compliance management, and interactions with ANVISA. Our specialists help organizations accelerate market entry while mitigating regulatory risk.
Whether you are a pharmaceutical company, biotechnology innovator, medical device manufacturer, or medical cannabis developer, ClarkeModet combines global expertise with local regulatory knowledge to help you confidently navigate Brazil’s evolving regulatory landscape and transform regulatory complexity into competitive advantage.
Brazil is opening new doors for global healthcare innovators. Contact our Regulatory Services team in Brazil to walk through them with confidence.